Monopar Therapeutics to Participate in the Maxim Group’s Healthcare Virtual Conference

Monopar Therapeutics to Participate in the Maxim Group’s Healthcare Virtual Conference

June 14, 2023 | Last Trade: US$38.75 0.73 1.92

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a one-on-one fireside chat with Jason McCarthy, PhD, Senior Managing Director of Equity Research, at the Maxim Group’s Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm ET.

Fireside Chat Details:
Date: June 20, 2023
Time: 1:30 pm ET
Location: Virtual Conference

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Stock Quote

Last Trade:	US$38.75
Daily Change:	0.73 1.92
Daily Volume:	1,425
Market Cap:	US$236.360M

March 31, 2025 Monopar Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments December 05, 2024 Monopar Therapeutics Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu December 03, 2024 Monopar Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference November 08, 2024 Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments October 28, 2024 Monopar Therapeutics Announces Proposed Public Offering of Common Stock LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE